Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial

被引：0

作者：

Paschke, R. ^{[1
]}

Brose, M. S. ^{[2
]}

Jarzab, B. ^{[3
,4
]}

Elisei, R. ^{[5
]}

Siena, S. ^{[6
]}

Bastholt, L. ^{[7
]}

de la Fouchardiere, C. ^{[8
]}

Pacini, F. ^{[9
]}

Nutting, C. ^{[10
]}

Shong, Y. K. ^{[11
]}

Sherman, S., I ^{[12
]}

Smit, J. W. A. ^{[13
]}

Chung, J. ^{[14
]}

Kappeler, C. ^{[15
]}

Molnar, I ^{[14
]}

Schlumberger, M. ^{[16
]}

机构：

[1] Univ Hosp Leipzig, Dept Endocrinol & Nephrol, Leipzig, Germany

[2] Univ Penn, Abramson Canc Ctr, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA

[3] Maria Sklodowska Curie Mem Canc Ctr, Gliwice, Poland

[4] Inst Oncol, Gliwice, Poland

[5] Univ Pisa, Dept Clin & Expt Med, Pisa, Italy

[6] Osped Niguarda Ca Granda, Milan, Italy

[7] Odense Univ Hosp, DK-5000 Odense, Denmark

[8] Hosp Civils Ctr Anticanc, Consortium Canc Thyroidien, Lyon, France

[9] Univ Siena, Unit Endocrinol, I-53100 Siena, Italy

[10] Royal Marsden Hosp, London SW3 6JJ, England

[11] Asan Med Ctr, Seoul, South Korea

[12] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[13] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, NL-6525 ED Nijmegen, Netherlands

[14] Bayer HealthCare Pharmaceut, Montville, NJ USA

[15] Bayer Pharma AG, Berlin, Germany

[16] Inst Gustave Roussy, Villejuif, France

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2014年 / 37卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V400

引用

页码：120 / 120

页数：1

共 50 条

[1] Updated overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib on the phase 3 DECISION trial.
Brose, Marcia S.
Jarzab, Barbara
Elisei, Rossella
Siena, Salvatore
Bastholt, Lars
De La Fouchardiere, Christelie
Pacini, Furio
Paschke, Ralf
Nutting, Christopher
Shong, Young Kee
Sherman, Steven I.
Smit, Johannes W. A.
Chung, John Woojune
Kappeler, Christian
Molnar, Istvan
Schlumberger, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[2] Final overall survival analysis of patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) treated with sorafenib in the phase 3 DECISION trial: An exploratory crossover adjustment analyses
Brose, M.
Jarzab, B.
Elisei, R.
Giannetta, L.
Bastholt, L.
de la Fouchardiere, C.
Pacini, F.
Paschke, R.
Nutting, C.
Shong, Y. K.
Sherman, S.
Smit, J.
Chung, J.
Meinhardt, G.
Schlumberger, M.
Kappeler, C.
ANNALS OF ONCOLOGY, 2016, 27
[3] Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): detailed analyses from the phase III DECISION trial
Kroiss, M.
Worden, F.
Shi, J.
Hadjieva, T.
Bonichon, F.
Gao, M.
Fugazzola, L.
Ando, Y.
Hasegawa, Y.
Park, D. J.
Nutting, C.
Sherman, S., I
Shong, Y. K.
Smit, J. W.
Chung, J.
Kapeller, C.
Molnar, I
Schlumberger, M.
Brose, M. S.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 269 - 269
[4] Safety and tolerability of sorafenib for treatment of locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC): Detailed analyses from the phase III DECISION trial.
Worden, Francis P.
Fassnacht, Martin
Shi, Yuankai
Hadjieva, Tatiana
Bonichon, Francoise
Gao, Ming
Fugazzola, Laura
Ando, Yuichi
Hasegawa, Yasuhisa
Park, Do Joon
Nutting, Christopher
Sherman, Steven I.
Shong, Young Kee
Smit, Johannes W. A.
Chung, John Woojune
Kappeler, Christian
Molnar, Istvan
Schlumberger, Martin
Brose, Marcia S.
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[5] Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase 3 DECISION trial
Brose, M. S.
Nutting, C.
Jarzab, B.
Elisei, R.
Siena, S.
Bastholt, L.
de la Fourchardiere, C.
Pacini, F.
Paschke, R.
Shong, Y. K.
Sherman, S. I.
Smit, J. W. A.
Chung, J.
Kappeler, C.
Molnar, I.
Schlumberger, M.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 130 - 131
[6] Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase 3 DECISION trial
Paschke, R.
Brose, M. S.
Nutting, C.
Jarzab, B. J.
Elisei, R.
Siena, S.
Bastholt, L.
de la Fouchardiere, C.
Pacini, F.
Shong, Y. K.
Sherman, S., I
Smit, J. W. A.
Chung, J.
Siedentop, H.
Molnar, I
Schlumberger, M.
ONKOLOGIE, 2013, 36 : 184 - 184
[7] Exploratory analysis of outcomes for patients with locally advanced or metastatic radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) receiving open-label sorafenib post-progression on the phase III DECISION trial
Paschke, R.
Schlumberger, M.
Nutting, C.
Jarzab, B.
Elisei, R.
Siena, S.
Bastholt, L.
de la Fouchardiere, C.
Pacini, F.
Shong, Y. K.
Sherman, S., I
Smit, J. W.
Chung, J.
Kappeler, C.
Molnar, I
Brose, M. S.
Oncology Research and Treatment, 2015, 38 : 186 - 186
[8] Population PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trial
Paschke, R.
Bastholt, L.
Brose, M. S.
Jarzab, B.
Schlumberger, M.
Siena, S.
de la Fouchardiere, C.
Deshpande, H.
Shi, Y.
Elisei, R.
Gao, M.
Li, L.
Prins, K.
Walker, H.
Mitchell, D.
Lettieri, J.
Molnar, I
Kappeler, C.
Pena, C.
ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 268 - 269
[9] Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial.
Brose, Marcia S.
Nutting, Christopher
Jarzab, Barbara
Elisei, Rossella
Siena, Salvatore
Bastholt, Lars
de la Fouchardiere, Christelle
Pacini, Furio
Paschke, Ralf
Shong, Young Kee
Sherman, Steven I.
Smit, Johannes W. A.
Chung, John Woojune
Siedentop, Harald
Molnar, Istvan
Schlumberger, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (18)
[10] Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer (DTC): The phase III DECISION trial
Bockisch, A.
Brose, M. S.
Nutting, C.
Jarzab, B.
Elisei, R.
Siena, S.
Bastholt, L.
de la Fouchardiere, C.
Pacini, F.
Paschke, R.
Shong, Y. K.
Sherman, S. I.
Smit, J. W.
Chung, J. W.
Kappeler, C.
Molnar, I.
Schlumberger, M.
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2014, 122 (03)

← 1 2 3 4 5 →